
Hepion Pharmaceuticals HEPA
Quarterly report 2025-Q3
added 11-12-2025
Hepion Pharmaceuticals Total Shareholders Equity 2011-2026 | HEPA
Annual Total Shareholders Equity Hepion Pharmaceuticals
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.86 M | 7.28 M | 49.9 M | 93 M | 40.5 M | 15.6 M | 1.98 M | 3.7 M | 1.32 M | 3.44 M | -2.93 M | -140 K | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 93 M | -2.93 M | 17.6 M |
Quarterly Total Shareholders Equity Hepion Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.32 M | 3.8 M | 3.9 M | -1.86 M | 407 K | 3.56 M | 7.52 M | 7.28 M | 16.2 M | 26.4 M | 37.2 M | 49.9 M | 59.3 M | 67.3 M | 86.6 M | 93 M | 103 M | 111 M | 118 M | 40.5 M | 40.5 M | 40.5 M | 40.5 M | 15.6 M | 15.6 M | 16.2 M | 16.2 M | 1.72 M | 1.98 M | 1.98 M | 1.98 M | 3.7 M | 3.7 M | 3.7 M | 3.7 M | 5.88 M | -3 M | 1.32 M | 1.32 M | 4.98 M | -1.36 M | 3.44 M | 3.44 M | 8.6 M | 540 K | -2.93 M | -2.93 M | -490 K | -323 K | -140 K | -140 K | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 118 M | -3 M | 20.8 M |
Total Shareholders Equity of other stocks in the Biotechnology industry
| Issuer | Total Shareholders Equity | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
AbCellera Biologics
ABCL
|
967 M | $ 3.52 | -1.26 % | $ 1.05 B | ||
|
MorphoSys AG
MOR
|
621 M | - | 2.43 % | $ 254 M | ||
|
Acorda Therapeutics
ACOR
|
-158 M | - | -24.86 % | $ 820 K | ||
|
Acasti Pharma
ACST
|
66.6 M | - | 4.01 % | $ 150 M | ||
|
Advaxis
ADXS
|
-24.4 M | - | -9.65 % | $ 45.9 M | ||
|
AC Immune SA
ACIU
|
215 M | $ 3.22 | 2.88 % | $ 229 M | ||
|
I-Mab
IMAB
|
1.72 B | - | - | $ 866 M | ||
|
Aeglea BioTherapeutics
AGLE
|
715 M | - | - | $ 1.01 B | ||
|
AgeX Therapeutics
AGE
|
5.47 M | - | -10.17 % | $ 12.2 K | ||
|
Biophytis SA
BPTS
|
2.27 M | - | -13.47 % | $ 169 M | ||
|
Albireo Pharma
ALBO
|
176 M | - | -0.23 % | $ 916 M | ||
|
Aileron Therapeutics
ALRN
|
54.4 M | - | 10.36 % | $ 9.8 M | ||
|
Aptorum Group Limited
APM
|
21.1 M | $ 0.8 | 1.81 % | $ 4.36 M | ||
|
ADC Therapeutics SA
ADCT
|
166 M | $ 4.13 | -1.67 % | $ 105 M | ||
|
Midatech Pharma plc
MTP
|
6.72 M | - | -18.52 % | $ 27.3 M | ||
|
Adverum Biotechnologies
ADVM
|
70.7 M | - | - | $ 86.2 M | ||
|
Alterity Therapeutics Limited
ATHE
|
35.5 M | $ 3.4 | -5.82 % | $ 8.18 B | ||
|
Ascendis Pharma A/S
ASND
|
884 M | $ 228.5 | -1.09 % | $ 5 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
29.5 M | - | - | $ 26.5 M | ||
|
Applied Molecular Transport
AMTI
|
60.8 M | - | - | $ 10.1 M | ||
|
Atea Pharmaceuticals
AVIR
|
275 M | $ 6.1 | 0.83 % | $ 497 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
214 M | $ 6.6 | -0.45 % | $ 181 M | ||
|
Akero Therapeutics
AKRO
|
750 M | - | - | $ 3.67 B | ||
|
Athersys
ATHX
|
16.4 M | - | 3.77 % | $ 22.4 M | ||
|
Akouos
AKUS
|
234 M | - | 0.23 % | $ 488 M | ||
|
Acer Therapeutics
ACER
|
-16.8 M | - | 2.71 % | $ 14 M | ||
|
ARCA biopharma
ABIO
|
382 M | - | 1052.0 % | $ 415 M | ||
|
Allena Pharmaceuticals
ALNA
|
18.9 M | - | 3.16 % | $ 1.9 M | ||
|
AlloVir
ALVR
|
113 M | - | 4.14 % | $ 49.1 M | ||
|
Anika Therapeutics
ANIK
|
212 M | $ 14.52 | 1.11 % | $ 213 M | ||
|
Aptinyx
APTX
|
38.3 M | - | -39.0 % | $ 4.57 M | ||
|
BioCardia
BCDA
|
-1.6 M | $ 1.3 | 2.36 % | $ 27.5 M | ||
|
Aptose Biosciences
APTO
|
-4.54 M | - | -45.71 % | $ 1.2 M | ||
|
AVEO Pharmaceuticals
AVEO
|
45.9 M | - | - | $ 521 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-1.1 M | - | - | $ 7.46 M | ||
|
Aytu BioScience
AYTU
|
19 M | $ 2.67 | 1.14 % | $ 16.8 M | ||
|
Avenue Therapeutics
ATXI
|
2.8 M | - | -52.27 % | $ 4.45 M | ||
|
Autolus Therapeutics plc
AUTL
|
427 M | $ 1.49 | -1.32 % | $ 380 M | ||
|
Athira Pharma
ATHA
|
44.8 M | - | - | $ 269 M | ||
|
BioNTech SE
BNTX
|
1.37 B | $ 92.62 | 2.3 % | $ 27.2 B | ||
|
CureVac N.V.
CVAC
|
688 M | - | - | $ 867 M | ||
|
Aravive
ARAV
|
10.7 M | - | -13.39 % | $ 1.45 M | ||
|
Burford Capital Limited
BUR
|
1.7 B | $ 8.28 | 2.73 % | $ 1.35 B | ||
|
AstraZeneca PLC
AZN
|
15.6 B | - | - | $ 96.9 B | ||
|
Actinium Pharmaceuticals
ATNM
|
32.8 M | $ 1.16 | 4.5 % | $ 34.9 M |